Cassava Sciences (PTIE) – StreetInsider.com Reports
-
Pain Therapeutics (PTIE) Announces Name Change to Cassava Sciences (SAVA)
-
Pain Therapeutics (PTIE) says FDA denies making math errors, material mistakes or misrepresentations during June Advisory Committee Meeting for REMOXY
-
Pain Therapeutics (PTIE) Secures $1.5M Research Grant by National Institutes of Health
-
Pain Therapeutics (PTIE) Reports Publication of Two New Peer-Reviewed Studies for REMOXY ER (extended-release oxycodone)
-
Pain Therapeutics (PTIE) Reports Commencement of Phase II Study in Alzheimer’s Disease
-
Pain Therapeutics (PTIE) Appeals FDA Decision on REMOXY
-
Pain Therapeutics (PTIE) Reports Appointment of Eric Schoen as Chief Financial Officer
-
Pain Therapeutics (PTIE) Secures $3.5M NIH Grant Award to Study Alzheimer’s Disease
-
Pain Therapeutics (PTIE) Awarded $3.5M NIH Alzheimer's Grant
-
Pain Therapeutics (PTIE) Announces 8.86M Share Registered Direct Offering at $1.15/Sh
-
Pain Therapeutics (PTIE) Secures $3.2M NIH Grant for Study of Alzheimer’s Disease
-
DURECT Corp (DRRX) Confirms Pain Therapeutics (PTIE) CRL for REMOXY ER
-
Pain Therapeutics (PTIE) Says FDA Issued CRL for REMOXY
-
Pre-Open Movers 06/27: (DFBG) (CARA) (I) Higher; (AQXP) (PTIE) (DRRX) Lower (more...)
-
Pain Therapeutics (PTIE) to Resume Trading at 6:05 pm ET
-
Pain Therapeutics (PTIE) Confirms FDA Voted 14 to 3 Against Approval of REMOXY ER
-
FDA Adcomm Votes 14-3 Against Approval of Pain Therapeutics's (PTIE) Remoxy ER
-
Pain Therapeutics (PTIE) Halted Ahead of FDA Panel on Remoxy ER
-
Pain Therapeutics (PTIE) Halted, News Pending
-
FDA Releases Briefing Documents on Pain Therapeutics' (PTIE) Remoxy ER Ahead of Panel
-
DURECT Corp (DRRX) Announces FDA Advisory Committee Meeting for REMOXY ER
-
Pain Therapeutics (PTIE) Reports Tentative FDA Advisory Committee Meeting Date for REMOXY ER on June 26, 2018
-
Pain Therapeutics (PTIE) REMOXY NDA Accepted by FDA, Sets August 7 PDUFA Date
-
DURECT Corp (DRRX) Announces Resubmission of REMOXY ER NDA by its licensee, Pain Therapeutics (PTIE)
-
Pain Therapeutics (PTIE) Resubmits NDA for REMOXY ER
-
Pain Therapeutics (PTIE) Halted Again on LUDP
-
Pain Therapeutics (PTIE) Halted Again on LUDP
-
Pain Therapeutics (PTIE) Adds to Gains, Up 130%
-
Pain Therapeutics (PTIE) Halted on LUDP, Shares Up 80%
-
Pain Therapeutics (PTIE) Reports Positive Top-line Results from Nasal Abuse Potential Study with REMOX
-
Pain Therapeutics (PTIE) Announces Positive Regulatory Meeting for REMOXY
-
Pain Therapeutics (PTIE) Reports New Publication on Alzheimer’s Disease
-
Pain Therapeutics (PTIE) to Meet with FDA to Discuss NDA for REMOXY ER on November 14
-
Feuerstein Skeptical of Pain Therapeutics (PTIE) Surge on Phase 1 Data
-
Pain Therapeutics (PTIE) Halted on LUDP
-
Pain Therapeutics (PTIE) Surges Following PTI-125 Phase 1 Study Completion
-
Pain Therapeutics (PTIE) Announces Successful Phase I Clinical Study for PTI-125 to Treat AD
-
Pain Therapeutics (PTIE) Reports FDA Clearance of Investigational New Drug (IND) Application for PTI-125
-
Pain Therapeutics (PTIE) 7-for-1 Reverse Stock Split Effective 05/09
-
Pre-Open Movers 03/21: (PTIE) (HTBX) (ESPR) Higher; (CALA) (OCUL) (GEL) Lower (more...)
-
Pain Therapeutics (PTIE) Surges Following Positive REMOXY Regulatory Guidance
-
Pain Therapeutics (PTIE) Tops Q3 EPS by 1c
-
Unusual 11 Mid-Day Movers 9/27: (GI) (DRRX) (KTOV) Higher; (CVM) (CZR) (AOI) Lower
-
Unusual 11 Mid-Day Movers 9/26: (ARRY) (SMMT) (ACTA) Higher; (PTIE) (DRRX) (SALE) Lower
-
Pre-Open Stock Movers 09/26: (ARRY) (CHMT) (GWPH) Higher; (PTIE) (DRRX) (SALE) Lower (more...)
-
Pain Therapeutics (PTIE) Announces Receipt of FDA Complete Response Letter for REMOXY ER (DRRX)
-
DURECT Corp (DRRX), Pain Therapeutics (PTIE) Remoxy ER doesn't qualify for FD&C Act exemption - FDA
-
Gabelli Downgrades Pain Therapeutics (PTIE) to Hold
-
Pain Therapeutics (PTIE) Reports Q2 Loss of $0.07/Share
-
Pain Therapeutics (PTIE) on Watch Amid DURECT (DRRX) Headlines
Back to PTIE Stock Lookup